Glycosyltransferase POMGNT1 deficiency strengthens N-cadherin-mediated cell-cell adhesion.
Antigens, CD
/ metabolism
Cadherins
/ metabolism
Cell Adhesion
/ genetics
Dystroglycans
/ metabolism
Glycomics
Glycosylation
Glycosyltransferases
/ deficiency
HEK293 Cells
Humans
MAP Kinase Signaling System
/ physiology
Mannose
/ chemistry
Muscular Dystrophies
/ genetics
N-Acetylglucosaminyltransferases
/ deficiency
Polysaccharides
Signal Transduction
/ physiology
p38 Mitogen-Activated Protein Kinases
/ metabolism
MEB
N-cadherin
N-glycosylation
O-mannosylation
POMGNT1
cell adhesion
dystroglycanopathy
glycosylation
glycosyltransferase
muscle–eye–brain disease
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
Historique:
received:
09
09
2020
revised:
08
02
2021
accepted:
16
02
2021
pubmed:
22
2
2021
medline:
31
8
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Defects in protein O-mannosylation lead to severe congenital muscular dystrophies collectively known as α-dystroglycanopathy. A hallmark of these diseases is the loss of the O-mannose-bound matriglycan on α-dystroglycan, which reduces cell adhesion to the extracellular matrix. Mutations in protein O-mannose β1,2-N-acetylglucosaminyltransferase 1 (POMGNT1), which is crucial for the elongation of O-mannosyl glycans, have mainly been associated with muscle-eye-brain (MEB) disease. In addition to defects in cell-extracellular matrix adhesion, aberrant cell-cell adhesion has occasionally been observed in response to defects in POMGNT1. However, specific molecular consequences of POMGNT1 deficiency on cell-cell adhesion are largely unknown. We used POMGNT1 knockout HEK293T cells and fibroblasts from an MEB patient to gain deeper insight into the molecular changes in POMGNT1 deficiency. Biochemical and molecular biological techniques combined with proteomics, glycoproteomics, and glycomics revealed that a lack of POMGNT1 activity strengthens cell-cell adhesion. We demonstrate that the altered intrinsic adhesion properties are due to an increased abundance of N-cadherin (N-Cdh). In addition, site-specific changes in the N-glycan structures in the extracellular domain of N-Cdh were detected, which positively impact on homotypic interactions. Moreover, in POMGNT1-deficient cells, ERK1/2 and p38 signaling pathways are activated and transcriptional changes that are comparable with the epithelial-mesenchymal transition (EMT) are triggered, defining a possible molecular mechanism underlying the observed phenotype. Our study indicates that changes in cadherin-mediated cell-cell adhesion and other EMT-related processes may contribute to the complex clinical symptoms of MEB or α-dystroglycanopathy in general and suggests that the impact of changes in O-mannosylation on N-glycosylation has been underestimated.
Identifiants
pubmed: 33610554
pii: S0021-9258(21)00206-4
doi: 10.1016/j.jbc.2021.100433
pmc: PMC7994789
pii:
doi:
Substances chimiques
Antigens, CD
0
CDH2 protein, human
0
Cadherins
0
Polysaccharides
0
Dystroglycans
146888-27-9
Glycosyltransferases
EC 2.4.-
N-Acetylglucosaminyltransferases
EC 2.4.1.-
protein O-mannose beta-1,2-N-acetylglucosaminyltransferase
EC 2.4.1.-
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Mannose
PHA4727WTP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100433Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
Trends Biochem Sci. 2015 Jul;40(7):351-9
pubmed: 26002999
Dev Dyn. 2018 Mar;247(3):473-480
pubmed: 28795450
EMBO Rep. 2004 May;5(5):484-9
pubmed: 15071496
Curr Opin Cell Biol. 2016 Aug;41:100-8
pubmed: 27161930
Nature. 2002 Jul 25;418(6896):417-22
pubmed: 12140558
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200510
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Mol Biol Cell. 2003 May;14(5):2088-103
pubmed: 12802077
Cells Tissues Organs. 2011;193(1-2):64-73
pubmed: 21051858
Mol Biol Cell. 2016 Mar 15;27(6):1026-39
pubmed: 26658610
Glycobiology. 2015 Jul;25(7):702-13
pubmed: 25882296
Mol Biol Cell. 2020 Feb 1;31(3):167-183
pubmed: 31851597
Mol Cell Biol. 2014 Sep 15;34(18):3486-99
pubmed: 25002532
J Biol Chem. 2019 Sep 27;294(39):14383-14393
pubmed: 31395657
J Clin Invest. 2009 Jun;119(6):1438-49
pubmed: 19487820
Nucleic Acids Res. 2013 Jan;41(Database issue):D1063-9
pubmed: 23203882
Curr Opin Pediatr. 2011 Dec;23(6):581-7
pubmed: 21970833
Nucleic Acids Res. 2011 Jul;39(12):e82
pubmed: 21493687
Matrix Biol. 2015 May-Jul;44-46:247-54
pubmed: 25805621
Cancer Biol Ther. 2015;16(1):125-36
pubmed: 25455932
Matrix Biol. 2015 May-Jul;44-46:200-6
pubmed: 25652204
Proc Natl Acad Sci U S A. 2017 Oct 17;114(42):11163-11168
pubmed: 28973932
Dev Dyn. 2008 Oct;237(10):2755-68
pubmed: 18773493
Matrix Biol. 2015 May-Jul;44-46:130-7
pubmed: 25701226
J Signal Transduct. 2012;2012:289243
pubmed: 22363839
Proc Natl Acad Sci U S A. 2016 Aug 16;113(33):9280-5
pubmed: 27493216
Differentiation. 1986;32(2):120-4
pubmed: 3792701
Exp Cell Res. 2006 Sep 10;312(15):2837-50
pubmed: 16857188
Oncotarget. 2016 Oct 4;7(40):65231-65246
pubmed: 27533452
Matrix Biol. 2014 Feb;34:144-53
pubmed: 24184828
Neuro Oncol. 2015 Feb;17(2):211-22
pubmed: 25085363
Annu Rev Cell Dev Biol. 2003;19:207-35
pubmed: 14570569
Acta Neuropathol. 2019 Dec;138(6):1033-1052
pubmed: 31463571
Nucleic Acids Res. 2012 Jul;40(Web Server issue):W117-22
pubmed: 22693217
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Anal Chem. 2018 Oct 16;90(20):11908-11916
pubmed: 30252445
J Biol Chem. 2009 Dec 11;284(50):34986-97
pubmed: 19846557
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12109-14
pubmed: 19587235
J Immunol. 1998 May 1;160(9):4175-81
pubmed: 9574517
Mol Cell Proteomics. 2019 Jul;18(7):1396-1409
pubmed: 31040225
Front Immunol. 2018 Nov 27;9:2754
pubmed: 30538706
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
J Cell Sci. 2012 May 15;125(Pt 10):2478-85
pubmed: 22344255
J Cell Sci. 2008 Mar 15;121(Pt 6):727-35
pubmed: 18322269
Methods Mol Biol. 2013;1018:107-10
pubmed: 23681621
Nat Rev Cancer. 2002 Jun;2(6):442-54
pubmed: 12189386
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21018-23
pubmed: 24101494
Nat Med. 2007 Aug;13(8):952-61
pubmed: 17660828
Development. 2015 Jun 15;142(12):2136-46
pubmed: 26015541
Proc Natl Acad Sci U S A. 2013 Dec 24;110(52):21024-9
pubmed: 24297939
Cell. 2010 May 28;141(5):897-907
pubmed: 20510933
Nat Rev Cancer. 2015 Sep;15(9):540-55
pubmed: 26289314
Nat Biotechnol. 2008 Mar;26(3):317-25
pubmed: 18278033
Can J Gastroenterol Hepatol. 2019 Dec 10;2019:1085717
pubmed: 31886153
Mech Dev. 2006 Mar;123(3):228-40
pubmed: 16458488
FASEB J. 2020 Jan;34(1):881-897
pubmed: 31914669
Biochem Biophys Res Commun. 2006 Dec 1;350(4):935-41
pubmed: 17034757
Front Oncol. 2016 Feb 17;6:33
pubmed: 26925388
Nat Rev Mol Cell Biol. 2020 Oct;21(10):607-632
pubmed: 32576977
Hypertension. 2002 Feb;39(2):233-8
pubmed: 11847190
J Comp Neurol. 2007 Mar 1;501(1):168-83
pubmed: 17206611
Biochim Biophys Acta. 2016 Aug;1860(8):1728-38
pubmed: 27038647
J Biochem. 2015 Jan;157(1):1-12
pubmed: 25381372
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Proc Jpn Acad Ser B Phys Biol Sci. 2019;95(1):39-51
pubmed: 30643095
Proteomics. 2018 Dec;18(24):e1800282
pubmed: 30427586
Small GTPases. 2011 Jan;2(1):51-53
pubmed: 21686283
Oncol Rep. 2017 Nov;38(5):2911-2918
pubmed: 29048655
Nat Rev Mol Cell Biol. 2012 Jun 22;13(7):448-62
pubmed: 22722607
J Vis Exp. 2014 Oct 17;(92):e51762
pubmed: 25350770
J Proteome Res. 2010 Dec 3;9(12):6655-64
pubmed: 20886907
Dev Cell. 2001 Nov;1(5):717-24
pubmed: 11709191
Chembiochem. 2017 Jul 4;18(13):1317-1331
pubmed: 28509371
FEBS Lett. 2013 Nov 15;587(22):3715-21
pubmed: 24113656